Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET.
马萨诸塞州剑桥，2024年5月6日（GLOBE NEWSWIRE）——罕见疾病细胞代谢和PK激活开创性疗法领域的领导者Agios Pharmicals, Inc.（纳斯达克股票代码：AGIO）今天宣布，该公司定于美国东部时间2024年5月16日星期四上午11点40分出席美银证券2024年医疗保健会议。
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at . A replay of the webcast will be archived on the company's website for at least two weeks following the presentation.
可以在公司网站 “投资者” 部分的 “活动与演讲” 下观看该演讲的网络直播，网址为。演讲结束后，网络直播的重播将在公司网站上存档至少两周。
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company's website at .
关于 Agios
Agios 是 PK 激活领域的先驱领导者，致力于为罕见疾病患者开发和提供变革性疗法。在美国，Agios为PK缺乏的成年人销售了同类首创的丙酮酸激酶（PK）激活剂，这是第一种针对这种罕见的、终身衰弱的溶血性贫血的疾病改善疗法。基于公司在传统血液学方面的深厚科学专业知识以及在细胞代谢和罕见血液学疾病领域的领先地位，Agios正在推进强大的临床研究药物产品线，其项目涉及α和β-地中海贫血、镰状细胞病、小儿PK缺乏症、MDS相关贫血和苯丙酮尿症（PKU）。除了临床产品线外，Agios 还在推进临床前 TMPRSS6 siRNA，将其作为真性红细胞增多症的潜在治疗方法。欲了解更多信息，请访问该公司的网站 。
Contacts:
联系人：
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
投资者联系人
Chris Taylor，投资者关系和企业传播副总裁
阿吉奥斯制药
IR@agios.com
Media Contact
Dan Budwick
1AB
dan@1abmedia.com
媒体联系人
丹·布德威克
1AB
dan@1abmedia.com